Professor Jane Kaye
BA, Grad Dip Leg, LLB, DPhil
Professor of Health, Law and Policy & Director, HeLEX
- Centre for Health, Law and Emerging Technologies (HeLEX)
Prof. Jane Kaye DPhil, LLB, Grad Dip Leg, BA is the Director of the Centre for Law, Health and Emerging Technologies (HeLEX) at the University of Oxford and a Wellcome Trust University Award holder. She obtained her degrees from the Australian National University (BA); University of Melbourne (LLB); and University of Oxford (DPhil). She was admitted to practice as a solicitor/barrister in 1997 and is a member of the University of Oxford’s Faculty of Law. She is on a number of international expert committees and scientific advisory boards and has been on the Nuffield Council Bioethics Working Group on Biodata (http://nuffieldbioethics.org/wp-content/uploads/Biological_and_health_data_web.pdf) and Rapporteur for the EC Expert Report, Biobanks for Europe - A Challenge for Governance, June 2012 (https://ec.europa.eu/research/swafs/pdf/pub_archive/biobanks-for-europe_en.pdf). She is also on the editorial boards of Law, Innovation and Technology, of the Journal of Law, Information and Science, of New Genetics & Society and of Life Sciences, Society and Policy. Her team are leading on the Dynamic Consent project and she is one of the leaders in the ELSI 2.0 Global Initiative. Her research focuses on the relationships between law, ethics and the emerging technologies in health. The main focus of her research is on genomics with an emphasis on biobanks, privacy, data-sharing frameworks, global governance and translational research.
Managing clinically significant findings in research: the UK10K example.
Kaye J. et al, (2014), Eur J Hum Genet, 22, 1100 - 1104
From patients to partners: participant-centric initiatives in biomedical research.
Kaye J. et al, (2012), Nat Rev Genet, 13, 371 - 376
Research priorities. ELSI 2.0 for genomics and society.
Kaye J. et al, (2012), Science, 336, 673 - 674
Kaye J. et al, (2012)
The regulation of direct-to-consumer genetic tests.
Kaye J., (2008), Hum Mol Genet, 17, R180 - R183
Marketing of unproven stem cell-based interventions: A call to action.
Sipp D. et al, (2017), Sci Transl Med, 9
The RUDY study: using digital technologies to enable a research partnership.
Teare HJA. et al, (2017), Eur J Hum Genet, 25, 816 - 822
Returning Results in Biobank Research: Global Trends and Solutions.
De Clercq E. et al, (2017), Genet Test Mol Biomarkers, 21, 128 - 131
Dynamic Consent: a potential solution to some of the challenges of modern biomedical research.
Budin-Ljøsne I. et al, (2017), BMC Med Ethics, 18
Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia.
Forestier-Zhang L. et al, (2016), Orphanet J Rare Dis, 11